seralutinib for Pulmonary arterial hypertension (PAH)

Inclusion criteria

• {"criterion_text":"- Adult female subjects aged 18 to 80 years, inclusive, or adult male subjects aged 50 to 80 years, inclusive, at the time of signing the informed consent form (ICF).\n- . Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable.\n- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study prior to initiation of any protocol-mandated procedures.\n- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n- Subjects must have completed a prior seralutinib PAH study and, in the opinion of the Investigator and Sponsor, have been compliant with study procedures and have completed treatment with IP through parent study EOT visit. See exception(s) for public health emergency visit/procedure delays specified in Appendix 6, Section 10.6.\n- Treatment with standard of care PAH disease-specific background therapies (stable dose).\n- Women of childbearing potential must have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) at extension enrollment visit before first administration of seralutinib in this study. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required, and results must be negative.\n- Women of nonchildbearing potential: Evidence of post-menopausal status. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy tubal ligation [if considered an effective form of sterilization in a specific country or region], or hysterectomy). − Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, tubal ligation [if considered an effective form of sterilization in a specific country or region], or hysterectomy).\n- Women of childbearing potential who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of contraception (defined in Appendix 4, Section 10.4) from consent through 30 days following the last administration of seralutinib; acceptable methods include hormonal contraception (oral contraceptives – as long as on stable dose, patch, implant, or injection), intrauterine devices or other form of highly effective contraception.\n- Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable.\n- Male subjects: Non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of seralutinib. Male subjects should refrain from sperm donation throughout this period (except for male subjects participating in fertility analysis as part of this protocol)."}

Exclusion criteria

• {"criterion_text":"- Medical Conditions: 1. Persistent and clinically significant systemic hypertension as evidenced by sitting systolic blood pressure > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg after a period of rest at the extension study initial visit, or hypotension as evidenced by systolic blood pressure < 90 mm Hg during the extension study initial visit. 2. Interval history of newly developed left-sided heart disease with onset or severity increased after participation in the parent study, and/or clinically significant cardiac disease, including but not limited to any of the following: a. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild aortic insufficiency, mild aortic stenosis (AS), mild mitral stenosis (MS), moderate mitral regurgitation (MR); b. Mechanical or bioprosthetic cardiac valve; c. Pericardial constriction or pericardial effusion with tamponade physiology; d. Restrictive or congestive cardiomyopathy; e. Left ventricular ejection fraction (LVEF) ≤50%. f. Symptomatic coronary disease; g. Significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation; h. Acutely decompensated left heart failure within 1 month (30 days) of extension enrollment visit; i. History of severe and untreated obstructive sleep apnea. 3. Potentially life-threatening cardiac arrhythmia with an ongoing risk. 4. Uncontrolled bacterial, viral, or fungal infections which require systemic therapy. 5. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or seralutinib administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study; including but not necessarily limited to the following: malignancy within 5 years of extension enrollment visit, with the exception of effectively treated or excised localized non-metastatic basal cell carcinoma of the skin and in situ carcinoma of the cervix; psychiatric disorder that compromises ability to give informed consent, substance abuse, coagulopathy, history of stroke, transient ischemic attack (TIA) requiring concurrent oral coagulation therapy, or intracranial hemorrhage; history of pulmonary embolus or deep vein thrombosis (DVT), history of vasovagal syncope with phlebotomy. 6. Currently pregnant or breastfeeding or intends to become pregnant during the duration of the study. 7. History of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Child-Pugh Class A or higher.\n- Current alcohol use disorder as defined by DSM-5, and/or history of current utilization of drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).\n- Have any other condition or reason that, in the opinion of the Investigator and/or the Sponsor’s Medical Monitor (or designee), would prohibit the subject from participating in the study. Diagnostic Assessments The most recent laboratory assessment from the parent study may be used to evaluate laboratory-associated exclusion criterion, if performed within 6 weeks (± 2 days) of the extension enrollment visit.\n- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN) or total bilirubin ≥ 2 × ULN.\n- Chronic renal insufficiency as defined by an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 via CKD-EPI (Levey, 2009) at extension study initial visit or requires dialytic therapy or hemofiltration.\n- Hemoglobin (Hgb) concentration < 8.5 g/dL.\n- Absolute neutrophil count (ANC) < 1 x 109/L.\n- Platelet count < 50 x 109/L.\n- Body weight ≤ 40 kg at extension study initial visit.\n- Use of inhaled prostanoids.\n- Chronic use of oral anticoagulants (ie, vitamin K antagonist such as warfarin or novel oral anticoagulant [NOAC]/direct oral anticoagulant [DOAC]); if on warfarin or a NOAC it is clinically acceptable to be withdrawn 1 month prior to start of GB002 (see Appendix 5, Section 10.5 for examples of prohibited anticoagulants).\n- Subjects with a history of severe milk protein allergy. In addition, subjects with known intolerance or hypersensitivity to lactose who, in the opinion of the Investigator, may experience severe symptoms following the ingestion of lactose."}

Primary endpoints

• {"endpoint_text":"- Incidence of treatment-emergent adverse events (TEAEs)","definition_or_measurement_approach":""}

Secondary endpoints

• {"endpoint_text":"- Change in the distance achieved on six-minute walk test (6MWT), (Δ6MWD)","definition_or_measurement_approach":"Change in six-minute walk distance (Δ6MWD) measured by the 6-minute walk test (6MWT)."}

Spain

Earliest CTIS Part Ii Submission Date

21-10-2024

Latest Decision Or Authorization Date

30-07-2025

Processing Time Days

282

Number Of Sites

2

Number Of Participants

4

Czechia

Earliest CTIS Part Ii Submission Date

21-10-2024

Latest Decision Or Authorization Date

29-07-2025

Processing Time Days

281

Number Of Sites

1

Number Of Participants

1

Germany

Earliest CTIS Part Ii Submission Date

21-10-2024

Latest Decision Or Authorization Date

29-07-2025

Processing Time Days

281

Number Of Sites

5

Number Of Participants

6

Primary sponsor

Full Name

GB002 Inc.

Organisation Type

Pharmaceutical company

Country Of Registered Address

United States

Contract research organisations

Name

PPD Development LP

Responsibilities

Multiple study operational functions (listed duties codes in file: 1,12,13,2,4,5,6).

Name

Worldwide Clinical Trials Early Phase Services LLC

Responsibilities

Biomarker analysis for safety PK; Code: 4

Name

4g Clinical LLC

Responsibilities

Trial Supply Management

Name

Medidata Solutions Inc.

Responsibilities

Clinical Database; other operational support

Third parties

• {"country":"United States","full_name":"Multi-Regional Clinical Trials Center Of Brigham And Women's Hospital And Harvard","duties_or_roles":"Echo Data Interpretation","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"PPD Development LP","duties_or_roles":"Codes: 1,12,13,2,4,5,6","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Worldwide Clinical Trials Early Phase Services LLC","duties_or_roles":"Biomarker analysis for safety PK; Code: 4","organisation_type":"Pharmaceutical company"}
• {"country":"United Kingdom (Northern Ireland)","full_name":"Almac Clinical Services Limited","duties_or_roles":"Trial Supply Depot for UK","organisation_type":"Pharmaceutical company"}
• {"country":"Belgium","full_name":"FluidDa","duties_or_roles":"Functional Respiratory Imaging (FRI) by HRCT","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"Clinical Database; Code: 7","organisation_type":"Non-Pharmaceutical company"}
• {"country":"Ireland","full_name":"Almac Clinical Services (Ireland) Limited","duties_or_roles":"Storage and distribution to clinical sites for EU","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"4g Clinical LLC","duties_or_roles":"Trial Supply Management","organisation_type":"Non-Pharmaceutical company"}
• {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"Electronic questionnaire","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"Cardiac Safety","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"PPD Development LP","duties_or_roles":"Codes: 1,12,6","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Greenphire LLC","duties_or_roles":"Travel and stipend","organisation_type":"Non-Pharmaceutical company"}
• {"country":"United States","full_name":"Dxterity Diagnostics Inc.","duties_or_roles":"Biomarkers","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Alturas Analytics Inc.","duties_or_roles":"Long term storage of patient samples","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"United Biosource LLC","duties_or_roles":"Code: 8","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"PPD Development LP","duties_or_roles":"Biomarker storage; Code: 4","organisation_type":"Pharmaceutical company"}
• {"country":"Belgium","full_name":"PPD Global Central Labs","duties_or_roles":"Biomarker storage; Code: 4","organisation_type":"Pharmaceutical company"}